Navigation Links
New therapies harness power of the immune system against cancer
Date:6/2/2014

CHICAGO New research on innovative immunotherapies for advanced or high-risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). These treatments used alone or in combination fight cancer by activating and amplifying the body's immune response to the disease.

The new studies find high activity with investigative drugs for advanced melanoma, and show for the first time that ipilimumab, a treatment already approved for advanced melanoma, can substantially decrease the risk of melanoma recurrence in certain patients with earlier-stage disease. In addition, another small trial reports that a one-time, personalized immunotherapy treatment induces complete and long-lasting remissions in a small number of women with advanced cervical cancer a disease with little to no effective treatment options.

"The field of immunotherapy has exploded in the last decade, and more and more patients are benefiting," said press briefing moderator Steven O'Day, MD, ASCO expert and clinical associate professor of medicine at the University of Southern California, Keck School of Medicine. "Having a potential new way to keep melanoma at bay is a major advance for patients who live under the constant fear of recurrence after surgery. It's also incredibly exciting that we're extending the benefits of immunotherapy beyond melanoma, to diseases like cervical cancer where patients urgently need better options."

Featured studies include:

  • Adjuvant ipilimumab improves recurrence-free survival in patients with high-risk stage III melanoma: Study marks the first time adjuvant (post-surgery) ipilimumab is shown to be effective in earlier-stage melanoma, though side effects are considerable.

  • PD-1 targeting immunotherapy MK-3475 has high and long-lasting activity against metastatic melanoma: Large phase I trial finds high survival rates in patients with advanced melanoma, including those previously treated with ipilimumab; one-year survival rate is 69 percent across all patient subgroups.

  • Combination immunotherapy with ipilimumab and nivolumab achieves long-term survival for patients with advanced melanoma: Updated follow-up data from an expanded phase I study show concurrent treatment with ipilimumab and the anti-PD-1 nivolumab yields strong, long-lasting responses and high survival rates.

  • HPV-targeted adoptive T cell therapy may provide a new personalized strategy for advanced cervical cancer: Early study of HPV-targeted immunotherapy shows promising activity in metastatic cervical cancer, a hard-to-treat disease with few effective treatment options.


'/>"/>

Contact: Kate Blackburn
Kate.Blackburn@asco.org
312-949-3232
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. Study examines adverse effects among different radiation therapies for prostate cancer
2. Moffitt researchers find cancer therapies affect cognitive functioning among breast cancer survivors
3. Doubt Cast on Usefulness of Sensory Therapies for Autism
4. Student researchers seek to develop new therapies for cancer
5. New Therapies Show Some Promise Against Pancreatic Cancer
6. University of Nevada School of Medicine researcher reviews muscular dystrophy therapies
7. Well-known author and historian reports on progress in Huntingtons therapies
8. Scientists develop mouse model that could lead to new therapies for liver cancer
9. $53 million grant will help health researchers develop new therapies -- with the publics help
10. New method may allow personalized clinical trial for cancer therapies
11. By studying animal health, researchers find improved ways for developing, testing cancer therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... Palm Beach, FL (PRWEB) , ... April 21, 2017 , ... The staff at Palm ... , will be taking part in the 2017 London Marathon. Set to take place on ... of charitable organizations. This year, Dr. Schwartz will run as part of team EMPOWER, raising ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy Programs , ... kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), which runs ... Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote presenters will ...
(Date:4/21/2017)... ... April 21, 2017 , ... Dudnyk has announced the launch of its new ... the full potential of specialty and orphan brands can only be achieved when the ... “The Unifying Effect is at the heart of a true partnership between our agency ...
(Date:4/21/2017)... ... 2017 , ... The VIA Agency , a full-service ... Theravent, Inc. , the makers of a revolutionary new device clinically proven to ... working to expand distribution in anticipation of a national launch. VIA will be ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 to ... and preventing substance use disorders. , The mission of AWARE is to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... Uro/Gyn and Gynecology markets with innovative and proprietary ... the Company as Senior Vice President, Marketing & ... Keswani will report directly to Darin Hammers ... is delighted that Ash has joined the Cogentix ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: